Oncolytics Biotech (NASDAQ:ONCY - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright's price objective suggests a potential upside of 395.05% from the company's previous close.
Oncolytics Biotech Price Performance
Oncolytics Biotech stock traded down $0.02 during mid-day trading on Thursday, hitting $1.01. The company's stock had a trading volume of 556,139 shares, compared to its average volume of 328,595. The business has a 50 day moving average price of $1.08 and a 200-day moving average price of $1.06. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.75. The stock has a market cap of $77.84 million, a price-to-earnings ratio of -3.81 and a beta of 1.69.
Hedge Funds Weigh In On Oncolytics Biotech
An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 51,889 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent reporting period. Institutional investors own 6.82% of the company's stock.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
